Linked Life Data

8983892

Source:http://linkedlifedata.com/resource/pubmed/id/8983892

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1997-1-7
pubmed:abstractText
Eighty-two patients with community-acquired pneumonia (CAP) or acute exacerbation (AE) of chronic bronchitis were randomized to receive ofloxacin (OFL) 400 mg twice daily (39 patients) versus 400 mg once daily (43 patients) orally. Cure rates showed no statistically significant difference (90.1 vs. 94.6%), but more patients receiving 800 mg/day had side effects. Thus, the once daily administration of OFL is equally effective and safer than 400 mg twice daily to treat CAP or AE chronic obstructive pulmonary disease, especially in countries with higher pneumococcal and Haemophilus influenzae resistance in community practice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0009-3157
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
227-30
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:articleTitle
Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis. A randomized multicenter study.
pubmed:affiliation
Department of Pneumology, University Hospital Trnava, Slovakia.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Multicenter Study